scholarly journals An aging pathway under IGF1‐R controls the TrkA to p75 neurotrophin receptor switch and amyloid‐β peptide generation

2006 ◽  
Vol 20 (5) ◽  
Author(s):  
Luigi Puglielli ◽  
Claudio Costantini ◽  
Heidi Scrable
2003 ◽  
Vol 23 (19) ◽  
pp. 7385-7394 ◽  
Author(s):  
Yan Zhang ◽  
Yanguo Hong ◽  
Younes Bounhar ◽  
Megan Blacker ◽  
Xavier Roucou ◽  
...  

2013 ◽  
Vol 8 (S1) ◽  
Author(s):  
Anne-Sophie Carlo ◽  
Camilla Gustafsen ◽  
Guido Mastrobuoni ◽  
Morten Nielsen ◽  
Stefan Kempa ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Abhisarika Patnaik ◽  
Marta Zagrebelsky ◽  
Martin Korte ◽  
Andreas Holz

2005 ◽  
Vol 391 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Claudio Costantini ◽  
Richard Weindruch ◽  
Giuliano Della Valle ◽  
Luigi Puglielli

Aging is the single most important risk factor for AD (Alzheimer's disease). However, the molecular events that connect normal aging to AD are mostly unknown. The abnormal accumulation of Aβ (amyloid β-peptide) in the form of senile plaques is one of the main characteristics of AD. In the present study, we show that two members of the neurotrophin receptor superfamily, TrkA (tyrosine kinase receptor A) and p75NTR (p75 neurotrophin receptor), differentially regulate the processing of APP (amyloid precursor protein): TrkA reduces, whereas p75NTR activates, β-cleavage of APP. The p75NTR-dependent effect requires NGF (nerve growth factor) binding and activation of the second messenger ceramide. We also show that normal aging activates Aβ generation in the brain by ‘switching’ from the TrkA to the p75NTR receptor system. Such an effect is abolished in p75NTR ‘knockout’ animals, and can be blocked by both caloric restriction and inhibitors of nSMase (neutral sphingomyelinase). In contrast with caloric restriction, which prevents the age-associated up-regulation of p75NTR expression, nSMase inhibitors block the activation of ceramide. When taken together, these results indicate that the p75NTR–ceramide signalling pathway activates the rate of Aβ generation in an age-dependent fashion, and provide a new target for both the understanding and the prevention of late-onset AD.


2012 ◽  
Vol 61 (8) ◽  
pp. 1289-1293 ◽  
Author(s):  
Thangiah Geetha ◽  
Chen Zheng ◽  
Wade C. McGregor ◽  
B. Douglas White ◽  
Maria T. Diaz-Meco ◽  
...  

2014 ◽  
Vol 56 ◽  
pp. 99-110 ◽  
Author(s):  
David Allsop ◽  
Jennifer Mayes

One of the hallmarks of AD (Alzheimer's disease) is the formation of senile plaques in the brain, which contain fibrils composed of Aβ (amyloid β-peptide). According to the ‘amyloid cascade’ hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of Aβ and towards smaller and more soluble ‘oligomers’ as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation of Aβ from the APP (amyloid precursor protein), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral Aβ, which is still the main hope for providing a more effective treatment for AD in the future.


Sign in / Sign up

Export Citation Format

Share Document